NEW YORK (GenomeWeb News) – German firm Medicyte today said that it has licensed lentiviral vector technology from Life Technologies for use in developing cell-based assays.

Medicyte said that it would incorporate the licensed technology into its Upcyte cell products for the biopharma and academic research markets. Financial and other terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.